Advertisement

Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil

      Abstract

      Objectives

      To investigate the impact of apolipoprotein E (apoE) genotype on the response of the plasma lipoprotein profile to eicosapentaenoic acid (EPA) versus docosahexaenoic acid (DHA) intervention in humans.

      Methods and results

      38 healthy normolipidaemic males, prospectively recruited on the basis of apoE genotype (n = 20 E3/E3 and n = 18 E3/E4), completed a double-blind placebo-controlled cross-over trial, consisting of 3 × 4 week intervention arms of either control oil, EPA-rich oil (ERO, 3.3 g EPA/day) or DHA-rich oil (DRO, 3.7 g DHA/day) in random order, separated by 10 week wash-out periods. A significant genotype-independent 28% and 19% reduction in plasma triglycerides in response to ERO and DRO was observed. For total cholesterol (TC), no significant treatment effects were evident; however a significant genotype by treatment interaction emerged (P = 0.045), with a differential response to ERO and DRO in E4 carriers. Although the genotype × treatment interaction for LDL-cholesterol (P = 0.089) did not reach significance, within DRO treatment analysis indicated a 10% increase in LDL (P = 0.029) in E4 carriers with a non-significant 4% reduction in E3/E3 individuals. A genotype-independent increase in LDL mass was observed following DRO intervention (P = 0.018). Competitive uptake studies in HepG2 cells using plasma very low density lipoproteins (VLDL) from the human trial, indicated that following DRO treatment, VLDL2 fractions obtained from E3/E4 individuals resulted in a significant 32% (P = 0.002) reduction in LDL uptake relative to the control.

      Conclusions

      High dose DHA supplementation is associated with increases in total cholesterol in E4 carriers, which appears to be due to an increase in LDL-C and may in part negate the cardioprotective action of DHA in this population subgroup.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bucher H.C.
        • Hengstler P.
        • Schindler C.
        • Meier G.
        N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.
        Am J Med. 2002; 112: 298-304
        • GISSI
        Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico.
        Lancet. 1999; 354: 447-455
        • Hu F.
        • Bronner L.
        • Willett W.
        • et al.
        Fish and omega-3 fatty acid intake and risk of coronary heart disease in women.
        J Am Med Assoc. 2002; 287: 1815-1821
        • Kris-Etherton P.
        • Harris W.
        • Appel L.
        Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.
        Arterioscler Thromb Vasc Biol. 2003; 23: E31-E42
        • Balk E.M.
        • Lichtenstein A.H.
        • Chung M.
        • et al.
        Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review.
        Atherosclerosis. 2006; 189: 19-30
        • Harris W.
        n-3 fatty acids and serum lipoproteins: human studies.
        Am J Clin Nutr. 1997; 65: 1645S-1654S
        • Minihane A.M.
        • Khan S.
        • Leigh-Firbank E.C.
        • et al.
        ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype.
        Arterioscler Thromb Vasc Biol. 2000; 20: 1990-1997
        • Minihane A.M.
        • Jofre-Monseny L.
        • Olano-Martin E.
        • Rimbach G.H.
        Apolipoprotein E genotype, cardiovascular risk and responsiveness to dietary fat manipulation.
        Proc Nutr Soc. 2007; 66: 183-197
        • Sarkkinen E.
        • Korhonen M.
        • Erkkila A.
        • Ebeling T.
        • Uusitupa M.
        Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol.
        Am J Clin Nutr. 1998; 68: 1215-1222
        • Leigh-Firbank E.C.
        • Minihane A.M.
        • Leake D.S.
        • et al.
        Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses.
        Br J Nutr. 2002; 87: 435-445
        • Jeon H.
        • Blacklow S.C.
        Structure and physiologic function of the low-density lipoprotein receptor.
        Annu Rev Biochem. 2005; 74: 535-562
        • Jackson K.G.
        • Maitin V.
        • Leake D.S.
        • Yaqoob P.
        • Williams C.M.
        Saturated fat-induced changes in Sf 60–400 particle composition reduces uptake of LDL by HepG2 cells.
        J Lipid Res. 2006; 47: 393-403
        • Henderson L.
        • Gregory J.
        • Irving K.
        • Swan G.
        The National Diet & Nutrition Survey: adults aged 19 to 64 years.
        HMSO, London2003
        • Hixson J.E.
        • Vernier D.T.
        Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
        J Lipid Res. 1990; 31: 545-548
      1. Lipid Research Clinics Program Manual of Laboratory Operations.
        DHEW Publications, 1975
        • Lindgren F.T.
        • Jensen L.C.
        • Hatch F.T.
        The isolation and quantitative analysis of serum lipoproteins.
        Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. 1972; : 181-274
        • Griffin B.A.
        • Caslake M.J.
        • Yip B.
        • et al.
        Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation.
        Atherosclerosis. 1990; 83: 59-67
        • Havel R.J.
        • Eder H.A.
        • Bragdon J.H.
        The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
        J Clin Invest. 1955; 34: 1345-1353
        • Folch J.
        • Lees M.
        • Sloane Stanley G.H.
        A simple method for the isolation and purification of total lipides from animal tissues.
        J Biol Chem. 1957; 226: 497-509
        • Hamilton J.G.
        • Comai K.
        Rapid separation of neutral lipids, free fatty acids and polar lipids using prepacked silica Sep-Pak columns.
        Lipids. 1988; 23: 1146-1149
        • Leake D.S.
        • Rankin S.M.
        The oxidative modification of low-density lipoproteins by macrophages.
        Biochem J. 1990; 270: 741-748
        • NCEP
        Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): final report.
        Circulation. 2002; 106: 3143-3421
        • Buckley R.
        • Shewring B.
        • Turner R.
        • Yaqoob P.
        • Minihane A.M.
        Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects.
        Br J Nutr. 2004; 92: 477-483
        • Grimsgaard S.
        • Bonaa K.H.
        • Hansen J.B.
        • Nordoy A.
        Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids.
        Am J Clin Nutr. 1997; 66: 649-659
        • Mori T.
        • Watts G.
        • Burke V.
        • et al.
        Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men.
        Circulation. 2000; 102: 1264-1269
        • Woodman R.J.
        • Mori T.A.
        • Burke V.
        • et al.
        Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension.
        Am J Clin Nutr. 2002; 76: 1007-1015
        • Nestel P.J.
        Fish oil and cardiovascular disease: lipids and arterial function.
        Am J Clin Nutr. 2000; 71: 228S-231S
        • Mori T.
        • Woodman R.
        The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk in humans.
        Curr Opin Clin Nutr Metab Care. 2006; 9: 95-104
        • Harris W.S.
        • Bulchandani D.
        Why do omega-3 fatty acids lower serum triglycerides?.
        Curr Opin Lipidol. 2006; 17: 387-393
        • Khan S.
        • Minihane A.M.
        • Talmud P.J.
        • et al.
        Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype.
        J Lipid Res. 2002; 43: 979-985
        • Chan D.C.
        • Watts G.F.
        • Mori T.A.
        • et al.
        Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity.
        Am J Clin Nutr. 2003; 77: 300-307
        • Harris W.S.
        • Connor W.E.
        • Illingworth D.R.
        • Rothrock D.W.
        • Foster D.M.
        Effects of fish oil on VLDL triglyceride kinetics in humans.
        J Lipid Res. 1990; 31: 1549-1558
        • Mori T.A.
        • Burke V.
        • Puddey I.B.
        • et al.
        Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men.
        Am J Clin Nutr. 2000; 71: 1085-1094
        • Huff M.W.
        • Telford D.E.
        Dietary fish oil increases conversion of very low density lipoprotein apoprotein B to low density lipoprotein.
        Arteriosclerosis. 1989; 9: 58-66
        • Demant T.
        • Bedford D.
        • Packard C.J.
        • Shepherd J.
        Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.
        J Clin Invest. 1991; 88: 1490-1501
        • Welty F.K.
        • Lichtenstein A.H.
        • Barrett P.H.
        • et al.
        Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans.
        Arterioscler Thromb Vasc Biol. 2000; 20: 1807-1810